Clascoterone Market Scope
Clascoterone, also known as Winlevi, is an antiandrogen medication used topically to treat acne. It is also being developed in a higher concentration under the brand name Breezula for the treatment of androgen-dependent scalp hair loss. The cream-like medication is applied to the skin, such as the face and scalp. Clascoterone is an androgen receptor (AR) antagonist or antiandrogen. Androgens such as testosterone and dihydrotestosterone have a biological target in the AR. It has very little systemic absorption when applied to the skin.
Attributes | Details |
---|
Study Period | 2019-2029 |
Base Year | 2023 |
Unit | Value (USD Million) |
Key Companies Profiled | Sun Pharmaceutical Industries Ltd. (India), Symbiotec (India), Aspen Pharmacare (South Africa), Teva Pharmaceuticals (Israel), Curia (United States), Bulat Pharmaceutical (India), Farmabios (Italy), SEQENS SAS (France), Shandong Sihuan Pharmaceutical (China) and Cosmo Pharmaceuticals (Ireland) |
CAGR | % |
To entice more end users, market players are focusing on providing clascoterone of higher quality while adhering to all regulatory standards. In the global clascoterone market, there are numerous large providers. They are also concentrating on the implementation of numerous advanced technologies in drug manufacturing and R&D. Furthermore, the numerous industry profits have led to the entry of new players, raising the level of rivalry in an already competitive market. The clascoterone market is currently expanding due to the rapid advancement of technology in pharmaceuticals. Some of the key players in this market follow strategies, which include new product offerings, product approvals, partnerships and alliances, mergers and acquisitions, and business expansions. Research Analyst at AMA estimates that france Players will contribute to the maximum growth of Global Clascoterone market throughout the predicted period.
Sun Pharmaceutical Industries Ltd. (India), Symbiotec (India), Aspen Pharmacare (South Africa), Teva Pharmaceuticals (Israel), Curia (United States), Bulat Pharmaceutical (India), Farmabios (Italy), SEQENS SAS (France), Shandong Sihuan Pharmaceutical (China) and Cosmo Pharmaceuticals (Ireland) are some of the key players that are part of study coverage.
About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.
Segmentation Overview
The study have segmented the market of Global Clascoterone market by Type , by Application (Acne and Hair loss) and Region with country level break-up.
On the basis of geography, the market of Clascoterone has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
region held largest market share in the year 2023.
Market Leaders and their expansionary development strategies
Sun Pharmaceutical Industries Limited received the certified copy of the order passed by the National Company Law Tribunal, Ahmedabad Bench in August 2021, approving the Scheme of Amalgamation and Merger of Sun Pharma Global FZE (Transferor Company), an indirect wholly-owned subsidiary of the Company with the company (Transferee Company), and their respective members and creditors (Scheme), for the merger of the Transferor Company with the Transferee Company.
The first-in-class topical treatment for acne vulgaris, clascoterone (Winlevi, Sun Pharmaceuticals) cream 1%, has officially launched in the United States. The topical androgen receptor inhibitor was first approved by the FDA in August 2020 to treat patients 12 years and older who have acne vulgaris. The cream launched in November 2021 in the United States.
PART 320 - BIOAVAILABILITY AND BIOEQUIVALENCE REQUIREMENTS Subpart B - Procedures for Determining the Bioavailability or Bioequivalence of Drug Products Sec. 320.21 Requirements for submission of bioavailability and bioequivalence data. (a) Any person submitting a full new drug application to the Food and Drug Administration (FDA) shall include in the application either: (1) Evidence measuring the in vivo bioavailability of the drug product that is the subject of the application; or (2) Information to permit FDA to waive the submission of evidence measuring in vivo bioavailability.
Influencing Trend:
Rise in Acne and Hair Loss at Young Age.
Market Growth Drivers:
Growing Hair Loss and Acne Problems has Been Driving the Market Growth.
Challenges:
Regulations for Approval and Approval Process will be challenging for Market Growth.
Restraints:
Known Side Effects of Drug will be Hindering the Market Growth.
Opportunities:
Investments in R&D and Product Development will be Bringing More Opportunities in Market.
Key Target Audience
Pharmaceutical companies, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others